Table 3 Provision of Vision Information Measurement tool (VIM)
Definition | Yes | No | N/A | Unable to answer |
|---|---|---|---|---|
Diagnosis Specific condition | ||||
Prognosis Its life-long implications for their prognosis for retention of sight | ||||
Prognosis That COAG in the early stages and OHT and suspected COAG are symptomless | ||||
Prognosis That most people treated for COAG will not go blind | ||||
Prognosis That once lost, sight cannot be recovered | ||||
Management The need for regular monitoring as specified by the healthcare professional | ||||
Management Methods of investigation during assessment | ||||
Management How long each appointment is likely to take and whether the person will need any help to attend (for example, driving soon after pupil dilation would be inadvisable) | ||||
Risk factors For example, that glaucoma can run in families and that family members may wish to be tested for the disease | ||||
Self-management The importance of the person’s role in their own treatment—for example, the ongoing regular application of eyedrops to preserve sight | ||||
Treatment The different types of treatment options, including mode of action, frequency | ||||
Treatment Severity of side effects, risks and benefits of treatment | ||||
Support Support groups | ||||
Support Information on how to access help with eyedrops and devices if required | ||||
Driver and Vehicle Licensing Agency (DVLA) regulations | ||||
Letter of Vision Impairment (LVI), Referral of Vision Impaired Patient (RVI) and Certificate of Vision Impairment (CVI) registration | ||||
Other | ||||
Other | ||||
Other | ||||
Other | ||||
Other |